Sensex
85,267.66 profit arw 449.53 (0.53%)
Nifty
26,046.95 profit arw 148.40 (0.57%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 14-Jun-2025
Hot Pursuit
14-Jun-2025     13:45

NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit

On conclusion of the inspection, the company received one observation in the Form-483.

The company believes that the observation is procedural in nature. The company is confident to address this observation comprehensively.

NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

The company's consolidated net profit increased 5.3% to Rs 406.60 crore on 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24.

The scrip had declined 1.26% to end at Rs 912.55 on the BSE on Friday.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

85,267.66 449.53 (0.53%)

Nifty

26,046.95 148.40 (0.57%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,976.80 446.28(1.75%)